The prescription drug negotiation provisions in the Inflation Reduction Act fulfill a long-standing policy goal for Democrats and grant the Medicare agency significant regulatory authority to lower prices for high-expenditure drugs, according to Margaux Hall, a partner in the health-care regulatory group at Ropes & Gray. Hall joins Bloomberg Intelligence analysts Duane Wright and Letitia Walker on this episode of the Votes and Verdicts podcast to discuss the potential impact of drug-pricing negotiation provisions on research and development and patient access to innovative therapies. Hall also shares her views on the possible effect for generic manufacturers and the influence of IRA pricing on non-Medicare markets.

See omnystudio.com/listener for privacy information.